Humalog Insulin (insulin lispro infusion) is a fast acting human insulin analog used to lower blood glucose. Insulin lispro is delivered by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli. Insulin lispro contrasts from human insulin in that the amino acid proline at position B28 is supplanted by lysine and the lysine in position B29 is supplanted by proline. Artificially, it is Lys(B28), Pro(B29) human insulin simple and has the experimental equation C257H383N65O77S6 and a sub-atomic load of 5808, both indistinguishable from that of human insulin.
HUMALOG is a quick acting human insulin simple showed to improve glycemic control in grown-ups and youngsters with diabetes mellitus.
Dose AND Organization
Significant Organization Directions
Continuously check insulin names before organization [see WARNINGS AND PRECAUTIONS].
Examine HUMALOG outwardly before use. It ought to show up clear and boring. Try not to utilize HUMALOG if particulate matter or shading is seen.
Try not to blend HUMALOG U-100 with different insulins when controlling utilizing a constant subcutaneous mixture siphon.
Try not to move HUMALOG U-200 from the KwikPen to a needle for organization [see WARNINGS AND PRECAUTIONS].
Try not to perform portion transformation when utilizing any HUMALOG U-100 or U-200 KwikPens. The portion window demonstrates the quantity of insulin units to be conveyed and no change is required.
Humalog U-100 and U-200 KwikPens are intended to dial portions in augmentations of 1 unit.
Humalog Junior KwikPen is intended to dial portions in 0.5 (1/2) unit increases.
Try not to blend HUMALOG U-200 with some other insulins.
Try not to oversee HUMALOG U-200 utilizing a nonstop subcutaneous mixture siphon (i.e., insulin siphon).
Try not to oversee HUMALOG U-200 intravenously.
Course Of Organization
Subcutaneous Infusion: HUMALOG U-100 Or U-200
Oversee the portion of HUMALOG U-100 or HUMALOG U-200 inside fifteen minutes before a dinner or following a feast by infusion into the subcutaneous tissue of the stomach divider, thigh, upper arm, or posterior. To decrease the danger of lipodystrophy, pivot the infusion site inside a similar locale starting with one infusion then onto the next [see ADVERSE REACTIONS].
HUMALOG directed by subcutaneous infusion ought to for the most part be utilized in regimens with a moderate or long-acting insulin.
Persistent Subcutaneous Implantation (Insulin Siphon): HUMALOG U-100 In particular
Try not to regulate HUMALOG U-200 utilizing a nonstop subcutaneous implantation siphon.
Oversee HUMALOG U-100 by nonstop subcutaneous mixture into the subcutaneous tissue of the stomach divider. Turn mixture locales inside a similar district to decrease the danger of lipodystrophy [see ADVERSE REACTIONS].
Follow medical care proficient proposals when setting basal and supper time imbuement rate.
Try not to weaken or blend HUMALOG U-100 while directing by ceaseless subcutaneous implantation.
Change HUMALOG U-100 in the pump reservoir at least at regular intervals.
Change the imbuement sets and the mixture set addition site something like at regular intervals.
Try not to uncover HUMALOG U-100 in the siphon supply to temperatures more noteworthy than 98.6°F (37°C).
Use HUMALOG U-100 in siphon frameworks reasonable for insulin imbuement [see PATIENT INFORMATION].
Intravenous Organization: HUMALOG U-100 In particular
Try not to regulate HUMALOG U-200 intravenously.
Weaken HUMALOG U-100 to fixations from 0.1 unit/mL to 1.0 unit/mL utilizing 0.9% sodium chloride.
Oversee HUMALOG U-100 intravenously Just under clinical watch with close observing of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia [see WARNINGS AND PRECAUTIONS and HOW SUPPLIED].
Individualize and change the measurements of HUMALOG dependent on course of organization, the person’s metabolic requirements, blood glucose checking results and glycemic control objective.
Measurement changes might be required with changes in active work, changes in supper designs (i.e., macronutrient substance or timing of food consumption), changes in renal or hepatic capacity or during acute illness [see WARNINGS AND PRECAUTIONS and Use In Explicit Populations].
Try not to perform portion change when utilizing any HUMALOG U-100 or U-200 KwikPens. The portion window demonstrates the quantity of insulin units to be conveyed and no change is required.
Dose Change Because of Medication Associations
Measurements change might be required when HUMALOG is coadministered with specific medications [see DRUG INTERACTIONS].
Measurements change might be required when changing from another insulin to HUMALOG [see WARNINGS AND PRECAUTIONS].